Source-grounded facts extracted from Vor Biopharma Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
David Zaccardelli was appointed as Director at Vor Biopharma Inc..
“On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.”
Andrew Levin resigned as Director at Vor Biopharma Inc..
“On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.”
Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.
“Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following votes: For Against Abstain 33,877,004 133,499 1,501”
Vor Biopharma Inc. shareholders approved Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan.
“Proposal 2 - Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan The Stockholders approved the Amended 2021 Plan by the following votes. For Against Abstain Broker Non-Votes 20,146,430 6,767,428 4,036 7,094,110”
Vor Biopharma Inc. shareholders approved Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D..
“Proposal 1 - Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. were each elected to serve as a member of the Board until the 2029 Annual Meeting of Stockholders and until his successor is duly elected or qualified, or, if sooner, until the director’s death, resignation or removal, by the following votes: Nominee For Withheld Broker Non-Votes Andrew Levin, M.D., Ph.D. 25,797,081 120,813 7,094,110 Fouad Namouni, M.D. 22,825938 4,091956 7,094,110”
Vor Biopharma Inc. issued 5,338,078 shares of common stock to TCGX for $14.05 per share.
“entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement.”
Vor Biopharma Inc. entered into Securities Purchase Agreement with entities affiliated with TCGX valued at approximately $75.0 million (effective 2026-03-26).
“On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Placement”).”
Vor Biopharma Inc. entered into Registration Rights Agreement with certain investors valued at Company obligated to file S-3 registration statement within 45 days of closing and use best efforts (effective 2025-12-15).
“In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated December 15, 2025 (the “Registration Rights Agreement”), with the Investors.”
Vor Biopharma Inc. entered into Securities Purchase Agreement with certain investors valued at 13,876,032 shares of common stock at $10.81 per share for gross proceeds of approximately $150.0 mil (effective 2025-12-15).
“On December 15, 2025, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 13,876,032 shares (the “Shares”) of the Company’s common stock, at a price per Share of $10.81, for gross proceeds of approximately $150.0 million (the “Private Placement”).”
Vor Biopharma Inc. issued 13,876,032 shares of common stock to institutional and accredited healthcare specialist investors for $10.81 per share, gross proceeds approximately $150 million.
“Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement.”
Vor Biopharma Inc.: Increased authorized common stock from 400,000,000 to 800,000,000 shares (effective 2025-05-22).
“On May 22, 2025, Vor Biopharma Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock (“Common Stock”) from 400,000,000 to 800,000,000.”
Robert Ang changed role as Principal Financial Officer and Principal Accounting Officer at Vor Biopharma Inc..
“On May 19, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s principal financial officer and principal accounting officer.”
Vor Biopharma Inc. announced a restructuring with charges of approximately $19.3 million affecting clinical and manufacturing operations (147 full-time employees, or approximately 95% of the Company’s current employee base).
“full-time employees, or approximately 95% of the Company’s current employee base (the “Wind Down”). The total costs related to the Wind Down are estimated to be approximately $19.3 million. The Company estimates that it will incur approximately $3.5 million in contract termination and other costs related to the discontinuation of its clinical trials, approximately”
Tirtha Chakraborty was terminated as Chief Scientific Officer and Head of Technical Operations at Vor Biopharma Inc..
“on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.”
Han Choi was terminated as Chief Financial Officer at Vor Biopharma Inc..
“on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.”
Vor Biopharma Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
“April 22, 2025, Vor Biopharma Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. The Company has 180 calendar days, or until October 20, 2025, to regain compliance with the minimum bid price requirement. To regain compliance”
Eyal C. Attar, M.D. resigned as Chief Medical Officer at Vor Biopharma Inc..
“On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the “Company”) of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.”
Erez Kalir was appointed as Director at Vor Biopharma Inc..
“On January 6, 2025 the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from seven to eight members and appointed Erez Kalir to fill the resulting vacancy, to serve on the Board as an independent Class III director until the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified.”
Han Choi was appointed as Chief Financial Officer at Vor Biopharma Inc..
“On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).”
Amy Quinlan was appointed as Interim Principal Accounting Officer at Vor Biopharma Inc..
“and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.”
Robert Ang was appointed as Interim Principal Financial Officer at Vor Biopharma Inc..
“On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer”
Nathan Jorgensen resigned as Chief Financial Officer at Vor Biopharma Inc..
“On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity.”
Fouad Namouni was appointed as Director at Vor Biopharma Inc..
“On April 30, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Fouad Namouni, M.D., to fill the resulting vacancy, to serve on the Board as an independent Class II director, until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified.”
Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-05-26 meeting.
“Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, by the following votes: Votes For Votes Against Abstentions 58,294,758 1,908 3,506”
Vor Biopharma Inc. shareholders approved Election of Two Class II Directors David C. Lubner and Joshua Resnick, M.D. at the 2023-05-26 meeting.
“by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes David C. Lubner 53,754,258 45,048 4,500,866 Joshua Resnick, M.D. 44,270,251 9,529,055 4,500,866”
Kush Parmar, M.D., Ph.D. resigned as member of the Board of Directors at Vor Biopharma Inc..
“On April 12, 2023, Kush Parmar, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation to the Board, effective immediately prior to the 2023 Annual Meeting of Stockholders of the Company.”
Vor Biopharma Inc. entered into At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated valued at up to $125.0 million (effective 2022-12-23).
“On December 23, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an At-the-Market Equity Offering Sales Agreement (the “ Agreement ”) with Stifel, Nicolaus & Company, Incorporated (“ Stifel ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “ Common Stock ”), having an aggregate offering price of up to $125.0 million after the date of the Agreement through Stifel as its sales agent.”
Vor Biopharma Inc. terminated Sales Agreement with Jefferies LLC (effective 2022-12-22).
“On December 9, 2022, Vor Biopharma Inc. (the “ Company ”) notified Jefferies LLC (“ Jefferies ”) of its decision to terminate the Open Market Sale Agreement SM , dated as of March 14, 2022, (the “ Sales Agreement ”) between the Company and Jefferies, effective as of December 22, 2022 (the “ Termination Date ”).”
Vor Biopharma Inc. entered into Securities Purchase Agreement with RA Capital Healthcare Fund, L.P. valued at approximately $50.0 million (effective 2022-12-07).
“On December 7, 2022, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with RA Capital Healthcare Fund, L.P. (“ RA Capital ”). Pursuant to the Securities Purchase Agreement, RA Capital agreed to purchase, and the Company agreed to issue to RA Capital 11,627,907 shares of Common Stock at a price of $4.30 per share (the “ Private Placement ”). The total purchase price shall be equal to approximately $50.0 million.”
Vor Biopharma Inc. entered into Underwriting Agreement with Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated valued at approximately $61.4 million (effective 2022-12-07).
“On December 7, 2022, Vor Biopharma Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “ Underwriters ”), relating to an offering (the “ Offering ”) of 15,302,267 shares (the “ Shares ”) of the Company’s common stock”
Christopher Slapak was terminated as Chief Medical Officer at Vor Biopharma Inc..
“On April 11, 2022, Vor Biopharma Inc. (the “Company”) and Christopher Slapak, M.D., Chief Medical Officer of the Company, agreed that Dr. Slapak’s employment with the Company will terminate effective May 6, 2022 in connection with Dr. Slapak’s retirement from the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.